This site is intended only for healthcare professionals resident in India
ZINFORO® (ceftaroline fosamil): Profiles of patients with cSSTI
Identify patients with cSSTI who may benefit from ZINFORO®
In patients with cSSTI, initial antimicrobial therapy failure is associated with 4 to 11 days longer
hospital stays and 4 to 12× higher mortality.1-3
Laura, a 71-year-old female, with diabetes and cellulitis, presents with tender erythematous, non-raised lesions.*
Martin, a 44-year-old male, readmitted to the hospital following inguinal hernia repair with purulent drainage from incision and localised pain.*
Mark, a 67-year-old male, admitted to the emergency room with a painful and fluctuant gluteal abscess.*
Please note: The examples described here are not actual patients, but fictitious representations of scenarios for which ZINFORO® could be considered.
*Refer to the local product document for further information on Zinforo®.4
BMI, body mass index; bpm, beats per minute; CAP, community-acquired pneumonia; CrCl, creatinine clearance; cSSTI, complicated skin and soft tissue infection; DM, diabetes mellitus; HbA1c, haemoglobin A1c; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; RR, respiratory rate; UTI, urinary tract infection.
Simple dosing with a flexible infusion time
Proven clinical efficacy in patients with
CAP and cSSTI
Safety profile consistent with other cephalosporins
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.